Azienda Sanitaria Locale Al Di Alessandria

At Azienda Sanitaria Locale Al Di Alessandria, clinical research is centered on cancer care, with studies exploring new ways to improve treatment outcomes, extend disease control, and better guide therapy choices across several tumor types.

• Studies in newly diagnosed multiple myeloma are evaluating maintenance approaches to help keep the disease under control after initial treatment.
• Research in non-small cell lung cancer is focused on testing whether newer immunotherapy combinations can improve treatment effectiveness after surgery and standard therapy.
• Investigations in ovarian cancer are examining maintenance treatment strategies and their role in delaying progression.
• The site also contributes to work in fallopian tube and primary peritoneal cancer, reflecting a broader interest in gynecologic oncology.

Overall, the trials at this hospital-based research site aim to refine maintenance therapy, strengthen immunotherapy options, and improve long-term outcomes for patients with advanced or recurrent malignancies.

Clinical trials in newly diagnosed multiple myeloma are assessing whether modern maintenance treatments can better preserve remission and delay relapse after first-line therapy.

• Comparisons of teclistamab with lenalidomide are designed to determine which maintenance strategy offers stronger disease control.
• The research is centered on improving progression-free survival and deepening response after transplant-based treatment.
• These studies aim to clarify the value of newer targeted and immune-based therapies in routine myeloma care.

This work supports a more personalized approach to hematologic cancer management by identifying maintenance options that may help patients remain in remission longer.

Research in non-small cell lung cancer at the site is focused on evaluating whether adding new immune-based treatment combinations can improve outcomes for patients after surgery and standard chemotherapy.

• Trials are examining the effectiveness of tiragolumab together with atezolizumab in patients with earlier-stage disease at higher risk of recurrence.
• The main goal is to test whether these immunotherapy approaches can better prevent the cancer from returning.
• The studies also look at overall treatment benefit in a setting where long-term disease control is especially important.

These investigations reflect a strong interest in advancing thoracic oncology through improved post-surgical treatment strategies.

Trials in BRCA wild-type advanced ovarian cancer and recurrent ovarian cancer are exploring how olaparib maintenance may help delay progression and support better disease management.

• One line of research is studying maintenance treatment in newly diagnosed advanced disease to understand its impact on progression-free survival.
• Another is evaluating whether treatment beyond progression can offer benefit after secondary cytoreductive surgery.
• The research also considers clinical and biological factors that may help predict which patients are most likely to benefit.

At Oncologia Ospedale S.Spirito- Casale Monferrato, this work contributes to more informed care in ovarian and related gynecologic cancers, with a focus on extending control of recurrent disease.